Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ARTICLES BY ED MISETA

  • Appili’s CRO Selection Reflects Realities of Clinical Studies in a Pandemic

    When Appili Therapeutics was ready to enter a Phase 3 trial for a COVID-19 treatment, the CRO selection process was tightly linked to the fact that the company would be conducting the study on infected patients during a global pandemic. 

  • 10 Years Of Progress In 10 Months: 2020 Was A Reset Year For Pharma

    A new report from McKinsey & Company highlights why 2020, despite the COVID-19 pandemic, was a banner year for innovation in drug development, and why we should be optimistic for the future of the industry. 

  • UCB Uses Decentralized Trials To Manage Studies

    UCB has a long history of conducting trials in immunology and neurology, with an emphasis in epilepsy. According to Tero Laulajainen, VP and head of global clinical science and operations for UCB, the company has a broad range of therapeutic expertise and numerous global trials, including studies in China. Therefore, the company expected to be impacted when news of the COVID-19 virus first began to make headlines. 

  • Why Did Veeva Become A Public Benefit Corporation?

    On February 1, 2021 Veeva Systems officially became a Public Benefit Corporation (PBC). With this move, it becomes the first technology company supporting life sciences to transition to a PBC and is also the first publicly traded corporation in any industry to make that move. How will the designation benefit he company?

  • How Ionis Pharmaceuticals Is Advancing Multiple Late-Stage Trials During COVID

    Ionis Pharmaceuticals has experienced substantial growth since its founding in 1990. The company used to boast that it had one drug for every 10 employees, from the cleaning staff up to the CEO. With the acquisition of Akcea Therapeutics in the fall of 2020, Ionis now has a pipeline of 47 products based on its antisense technology platform, which allows for the rapid discovery of new drugs. 

  • AI And Machine Learning Prepare Pharma For The Data Onslaught

    When I reached out to several clinical executives in my network for their thoughts on trends that will impact trials in the coming year, the two mentioned most frequently were AI and decentralized trials.

  • Janssen’s Best Practices For Patient Diversity Success

    The public's understanding of clinical research has increased as a result of the pandemic. However, that will not necessarily lead to improved patient recruitment in trials, especially among the much-needed minority populations. Cassandra Smith, director, diversity and inclusion in clinical trials at Janssen, believes future recruitment efforts will require heart and will need to lead with humility and empathy. 

  • Zogenix Puts Focus On Safety In Seizure Patients

    When Zogenix was planning its clinical trials for Fintepla, the safety of patients was a major concern. COO Ashish Sagrolikar discusses the precautions put in place, and adjustments that had to be made when conducting trials during a pandemic.

  • Is AI Improving Outcomes In Clinical Trials?

    In October 2020, I hosted a webinar on the topic of AI and how it will improve outcomes in clinical trials. This article highlights some of the comments from that discussion.

  • The Decentralized Trials & Research Alliance Hopes To Advance Studies

    Amir Kalali and Craig Lipset spent a good portion of 2020 reaching out to pioneers in the clinical space who were working on decentralized trials. Conversations centered on what more could be done to scale their use. They worked together to create the Decentralized Trials & Research Alliance (DTRA) to accelerate the adoption of decentralized methodologies in research.